Company Data

GenVec Inc.

Current Price
Market Cap
Price Target
Refer to Report
52wk Range
$2.7 - $10.44
Advanced Market Data


Genvec Inc was incorporated under the laws of the state of Delaware on December 7, 1992.The Company is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. Its development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus or RSV, herpes simplex virus or HSV, and malaria. In the area of animal health the Company is developing vaccines against foot-and-mouth disease or FMD. In collaboration with Novartis, the Companys hearing and balance disorders program is focused on the restoration of hearing and balance function through the regeneration of critical cells of the inner ear.

Research Reports

    Inbox Intel from Channelchek.

    Informed investors make more money. And itโ€™s all about timing. Get it when it happens.

    By clicking submit you are agreeing to the Terms of Use and Privacy Policy
    ยฉ 2018-2023 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.